Banyan Biomarkers Announces Publication of ALERT-TBI Clinical Study Results in The Lancet Neurology
Banyan Biomarkers, Inc., a pioneer in developing biomarkers for traumatic brain injury (TBI), today announced the publication of the results for the ALERT-TBI study, an international, multicenter clinical trial utilizing the Banyan Brain Trauma Indicator® (Banyan BTI™). The Banyan BTI is a diagnostic blood test used to rule out the need for a head CT scan in patients 18 years of age and older with a suspected TBI. The results, published in The Lancet Neurology, support the clinical role of the biomarker test for ruling out the need for a head CT scan among emergency department TBI patients who would normally receive a head CT scan.
The ALERT-TBI study enrolled patients at 22 independent clinical sites in the United States and Europe and compared the Banyan BTI test's results to head CT scans of patients presenting to emergency departments with suspected head injury. Analysis of 1,959 patients presenting with an initial Glasgow Coma Scale of 9-15 from the study showed that the Banyan BTI achieved high sensitivity (97.6%) and high negative predictive value (NPV) (99.6%) for ruling out the need for a head CT scan in these patients.
Banyan BTI identifies two brain-specific protein biomarkers Ubiquitin Carboxy-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) that are detected in the blood soon after a brain injury. In February, the U.S. Food and Drug Administration (FDA) granted marketing authorization to Banyan Biomarkers for the commercialization of Banyan BTI to aid in the evaluation of patients with a suspected mild TBI or concussion. There is another biomarker, S100B, that has limited adoption in Europe but is not approved for use in the United States.
“This blood test meets an important public health need to reduce the number of unnecessary CT scans particularly among those with mild TBI—also called concussion—who make up over 85% of all TBIs. In emergency medicine, CT scans are often used in evaluating these patients, even though fewer than 10 percent of scans reveal an abnormality,” said Jeff Bazarian, MD, MPH, principal investigator of the study, one of the lead authors on the publication, and professor of Emergency Medicine and Neurology at The University of Rochester School of Medicine. “This extensive clinical study shows that these two blood-based brain biomarkers can predict the absence of intracranial injury and reduce unnecessary head CT scanning, thereby reducing radiation exposure and healthcare costs while improving patient care and emergency department efficiency.”
“This large, prospective, multicenter trial validated the ability of the Banyan BTI to rule out the need for head CT scan in patients with a suspected TBI within 12 hours after injury. The FDA reviewed and authorized for marketing the test in fewer than six months as part of its Breakthrough Devices Program,” said Henry L. Nordhoff, Chairman and CEO of Banyan Biomarkers. “We are working closely with our commercial partners to make the test available in hospitals and emergency departments.”
The company is also engaged in additional TBI studies to evaluate the biomarkers in sports concussions, in adolescents, and for monitoring recovery from brain injury.
The clinical study was supported by the U.S. Army Medical Research and Materiel Command under Contract No. W81XWH-10-C-0251. Any views, opinions, conclusions, and/or findings contained in this press release are those of Banyan Biomarkers, Inc. and should not be construed as an official Department of the Army position, policy, or decision, unless so designated by other documentation.
About Traumatic Brain Injury (TBI)
Falls, automobile accidents, sports-related injuries, assaults, and, in the military, improvised explosive devices (IEDs) and combat wounds are common causes of TBI. The U.S. Center for Disease Control estimates there are more than 2.5 million emergency room visits in the United States because of head injuries and TBI is an economic burden of more than $76 billion annually on the healthcare system.1 Traumatic brain injury is the leading cause of disability and the number one cause of death for young adults.2
About Banyan Biomarkers
Banyan Biomarkers, Inc. has developed the first blood test, Banyan BTI™, that can be used by physicians to objectively aid in the evaluation of patients with suspected traumatic brain injury (TBI), also known as concussions. Banyan BTI consists of two test kits (Banyan UCH-L1® Kit and Banyan GFAP® Kit) that measure two specific protein biomarkers that rapidly appear in the blood after a brain injury. To learn more about the Company and Banyan BTI, visit www.banyanbio.com.
Banyan Biomarkers, Banyan, Brain Trauma Indicator, BTI, Banyan UCH-L1, Banyan GFAP, and the brain and tree logos are the trademarks and copyrights of Banyan Biomarkers, Inc.
Vice President of Business Development
Banyan Biomarkers, Inc.
+1 (760) 710-0423
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
+1 (858) 344-8091
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
United Nations Climate Action Award Goes to Germany for the First Time11.12.2018 19:00 | Pressemelding
Within the context of the United Nations Framework Convention on Climate Change, two ProVeg projects were awarded the Momentum for Change Climate Action Award 2018 in the category Planetary Health. One of these is the health promotion project Aktion Pflanzen-Power, jointly initiated with BKK ProVita. ProVeg and its partner received the award for their work in schools. It marks the first time that this award has gone to Germany. The award ceremony took place yesterday in the Polish city of Katowice as part of the 24th UN Climate Change Conference. ProVeg and BKK ProVita promote children’s health and climate action Aktion Pflanzen-Power aims to improve the availability and quality of vegan and vegetarian dishes in schools. Together with BKK ProVita, ProVeg has so far reached 24,800 students at 41 schools throughout Germany on the subject of wholesome, plant-based nutrition as part of the health promotion project. Healthy nutrition with Aktion Pflanzen-Power Andreas Schöfbeck, member of t
Thales and Gemalto are granted regulatory clearance by the European Commission11.12.2018 17:01 | Pressemelding
Regulatory News: Reference is made to the joint press release by Thales (Euronext Paris: HO) and Gemalto (Euronext Amsterdam and Paris: GTO) dated 27 March 2018 in relation to the launch of the recommended all-cash offer by Thales for all the issued and outstanding shares of Gemalto (the “Offer”), the publication of the Offer Document, and the joint press release of Thales and Gemalto dated 10 August 2018 in relation to the further extension of the Acceptance Period. Terms not defined in this press release will have the meaning as set forth in the Offer Document. Thales and Gemalto announce today that they have been granted merger control Regulatory Clearance by the European Commission, following Thales’s commitment to divest its general purpose hardware security modules (GP HSM) business globally1 to a suitable purchaser. This clearance is effective immediately. Together with the merger control clearances obtained in China, Israel, South Africa and Turkey, and clearances relating to f
Starr Insurance Companies Expands Aviation Insurance Operations to Brazil11.12.2018 15:43 | Pressemelding
Starr Insurance Companies today announced that Starr International Brasil Seguradora S.A. (“Starr Brazil”) has been granted a local license to offer aviation insurance. “We are thrilled to be adding aviation capability in an important, growing economy like Brazil,” stated Steve Blakey, president and chief executive officer for Starr Insurance Holdings, Inc. “As a worldwide leader in aviation insurance solutions, we are constantly seeking new opportunities and markets to meet the growing needs of the aviation and aerospace industry around the globe.” Fernanda Strachino, aviation specialist underwriter, has joined Starr Brazil to head the new aviation division. Fernanda brings more than 16 years’ of experience in the aviation and insurance market. Starr Brazil will offer a variety of aviation coverages, including: Aircraft Hull & Liability; Spare Parts; Third-Party Legal Liability; Corporate Non-Owned Aircraft Liability; General Liability; RETA Insurance (Mandatory Liability), Hangarkeep
Andersen Global Continues Growth in United Kingdom With Claritas Tax Limited11.12.2018 14:30 | Pressemelding
Today, Andersen Global expanded its reach in the United Kingdom with the addition of Claritas Tax Limited, a tax advisory and compliance services firm based in Birmingham, the second largest city in the country. Claritas is the fourth firm collaborating with Andersen Global in the UK. “Adding a sought-after firm like Claritas is not only a logical extension for Andersen Global, but it broadens our offering in the UK. Their practice focuses on corporation tax, R&D tax reliefs, mergers and acquisitions, private equity and venture capital in addition to serving individuals,” said Mark Vorsatz, Andersen Global Chairman and Andersen Tax LLC CEO. “Iain Wright and his team enhance our already robust core competences in the UK, a critical market for our clients, and we look forward to working with Claritas on a number of upcoming corporate opportunities.” Founded in 2012, Claritas Tax Limited is an advisory led business that provides a full range of tax advisory and compliance services to entr
Seoul Semiconductor Wins Patent Litigation against Everlight in Germany and Is Awarded Statutory Litigation Costs11.12.2018 14:00 | Pressemelding
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890) (“Seoul”), a leading global innovator of LED products and technology, announced that it won a patent litigation against Everlight Electronics Co., Ltd. (“Everlight”) in Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181211005233/en/ Seoul Semiconductor's Headquarters in Korea (Photo: Business Wire) The patent involved in this litigation relates to an LED package structure for thermal dissipation. Everlight purchased this patent from a U.S. company in 2017, and subsequently brought a patent lawsuit against Seoul in the Manheim Court of Germany. In December 2018, however, the Manheim Court ruled in favor of Seoul and ordered that Everlight, as the losing party, should bear the statutory costs of the court proceeding. In the United Kingdom, Seoul had already won a patent litigation against Everlight earlier this year. At that time, the UK Patent Court also ordered that Ever
Zodiac Appoints Derek Harrar CEO11.12.2018 14:00 | Pressemelding
Zodiac, a software vendor serving video service providers, announced today it has appointed Derek Harrar to serve as the Company’s Chief Executive Officer, effective immediately. Mr. Harrar has been on Zodiac’s board of directors since 2015, having being appointed at the time of One Equity Partners’ investment in the Company. “Derek’s considerable video industry operational and technology experience, rigorous execution and creativity are exactly what Zodiac needs for its next stage of growth, complementing the team we have put in place since our original investment,” said Andrew Dunn, Managing Director at One Equity Partners. Zodiac’s historic focus has been engineering software solutions for major video service providers in North America. This software experience, spanning a broad range of video technology permutations, is unique in the video distribution industry. More recently, Zodiac productized its carrier-grade cloud and client platform, enabling rapid and flexible deployment at